Pharma Packaging and Labelling Compliance Conference

Fleming Europe23 - 25 March 2011, Barcelona, Spain.
As pharmaceutical and patient landscape is constantly developing worldwide, excellence in strategic packaging and labelling has become essential to regulatory compliance, patient adherence, safety and sustainability.

Fleming Europe has selected from across the globe the highest-level pharmapack specialists, who will share their many market-specific local interpretations, which will influence pharmaceutical packaging and labelling structurally in 2011.

Listen to them speaking about the latest regulations coming into effect in the next months (including PharmaBraille and 2D Datamatrix Marking System). Discover various ways of patient adherence and the business models of in-house vs. outsourced artwork management. Be part of interactive roundtables focusing on the most advanced technologies of pharmapack traceability.…and listen to real-life case studies of anti-counterfeiting, parallel trade and packaging sustanability.

This 3-Day-Event includes a target audience focused post-conference workshop in 2 streams, which will bring together innovative, responsible and cost-effective methods of pharmaceutical and medical packaging, addressing key labelling issues as well as creating partnerships between industry leaders.

Key speakers:

  • Executive Director, Healthcare Compliance Packaging Council (HCPC), Austria
  • Director, Global Regulatory Affairs Strategic Policy & Support, Johnson&Johnson, UK
  • Secretary General, Child-Safe Packaging Group, UK
  • Head of Packaging Strategy, Global Pharma Operations, Novartis, Switzerland
  • Head of Patient Information Quality, MHRA, UK
  • Director of Materials and Packaging Quality System, Eli Lilly, USA
  • Director of Healthcare Traceability, GS1 Global, UK
  • Head of Pharmacy Trade Sector, Roche Diagnostics, Germany

Key topics:

  • Packaging & Labelling Regulatory Updates
  • Patient Adherence
  • Excellence in Artwork Management: In-house vs. Outsourced
  • Traceability to Combat Non-compliance
  • Packaging suitable for the Blind – Braille-Guidelines according to the European standards implemented from October 2010
  • Innovative 2D Datamatrix System for Pharma Traceability
  • Anti-Counterfeiting using Advanced Technology
  • Parallel Traders Perspectives
  • Sustainable Packaging Innovations
  • Child-safe vs. Senior friendly Packaging – Balancing Patients’ Needs
  • Information based Packaging Redesign

Who should attend:
VPs, Directors, Heads and Managers of Packaging, Labelling, Supply Chain and Logistics, Regulatory Affairs and Compliance, Quality Assurance, Product Information, Product Development, Operations, Quality Control and Assurance, Licensing, Marketing and Sales, Patient Compliance, Purchase / Facilities, Manufacturing Technology, International Labelling Liaison, Packaging Designer, Global Labelling.

For further information and registration, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/pharma-packaging-and-labelling-compliance-conference

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...